3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

F. Cardoso a, , A. Costa b, , E. Senkus , M. Aapro , F. Andr e , C.H. Barrios , J. Bergh , G. Bhattacharyya , L. Biganzoli , M.J. Cardoso , L. Carey , D. Corneliussen-James , G. Curigliano , V. Dieras , N. El Saghir , A. Eniu , L. Fallowfield , D. Fenech , P. Francis , K. Gelmon , A. Gennari , N. Harbeck , C. Hudis , B. Kaufman , I. Krop , M. Mayer , H. Meijer , S. Mertz , S. Ohno , O. Pagani , E. Papadopoulos , F. Peccatori b, , F. Pernault-Llorca , M.J. Piccart , J.Y. Pierga , H. Rugo , L. Shockney , G. Sledge , S. Swain , C. Thomssen , A. Tutt , D. Vorobiof , B. Xu , L. Norton , E. Winer z

[1]  A. Vigano,et al.  A Practical Approach to Fatigue Management in Colorectal Cancer , 2017, Clinical colorectal cancer.

[2]  M. Dowsett,et al.  Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Diest,et al.  Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer , 2016, Modern Pathology.

[4]  F. Cardoso,et al.  Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: Results from the Count Us, Know Us, Join Us and Here & Now surveys. , 2016, Breast.

[5]  S. Chandarlapaty,et al.  Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study , 2016, Breast Cancer Research and Treatment.

[6]  A. Urruticoechea,et al.  PHEREXA: A phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting. , 2016 .

[7]  A. Soran,et al.  A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). , 2016 .

[8]  K. Gelmon,et al.  PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). , 2016 .

[9]  M. Chambers,et al.  Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): Results of the SWISH trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Schroeder,et al.  Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011. , 2016, JAMA surgery.

[11]  J. Grenier,et al.  A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  S. Loi,et al.  Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Schneeweiss,et al.  Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. , 2016, The Lancet. Oncology.

[14]  M. de Boer,et al.  In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  F. Akiyama,et al.  Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer , 2016, Surgery Today.

[16]  M. Colleoni,et al.  Clinical overview of metronomic chemotherapy in breast cancer , 2015, Nature Reviews Clinical Oncology.

[17]  I. Mittra,et al.  Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. , 2015, The Lancet. Oncology.

[18]  C. Hudis,et al.  1802 Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC) , 2015 .

[19]  M. Piccart,et al.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Adam P Dicker,et al.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  F. Backx,et al.  Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial , 2015, BMC Medicine.

[22]  John D. Roberts,et al.  CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. , 2015 .

[23]  E. Perez,et al.  The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis. , 2015 .

[24]  E. Perez,et al.  Phase III, randomized study of trastuzumab emtansine (T-DM1) {+/-} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. , 2015 .

[25]  P. Jacobsen,et al.  Screening, evaluation, and management of cancer‐related fatigue: Ready for implementation to practice? , 2015, CA: a cancer journal for clinicians.

[26]  E. Perez,et al.  Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Massimo Cristofanilli,et al.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.

[28]  P. Neven,et al.  Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  J. Bergh,et al.  Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology. , 2014, European journal of cancer.

[30]  M. Piccart,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  B. E. van den Borne,et al.  Management of fatigue in patients with cancer -- a practical overview. , 2014, Cancer treatment reviews.

[32]  D. Rayson,et al.  Trastuzumab Beyond Progression for HER2 Positive Metastatic Breast Cancer: Progression‐Free Survival on First‐Line Therapy Predicts Overall Survival Impact , 2014, The breast journal.

[33]  W. Gradishar,et al.  Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Sung-Bae Kim,et al.  Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[35]  Thomas Bachelot,et al.  Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.

[36]  Sharyl J. Nass,et al.  Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis , 2014 .

[37]  S. Donofrio,et al.  Management of fatigue in patients with cancer , 2014 .

[38]  H. Rugo,et al.  The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer , 2014, BMC Cancer.

[39]  M. Piccart,et al.  Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. , 2013, Clinical breast cancer.

[40]  D. Amadori,et al.  Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. , 2013, The Lancet. Oncology.

[41]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.

[42]  G. Viale,et al.  Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status. , 2013, Breast.

[43]  P. Wiffen,et al.  Interventions for fatigue and weight loss in adults with advanced progressive illness. , 2017, The Cochrane database of systematic reviews.

[44]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[45]  I. Ray-Coquard,et al.  Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Robert B Livingston,et al.  Combination anastrozole and fulvestrant in metastatic breast cancer. , 2012, The New England journal of medicine.

[47]  C. Hudis,et al.  1st International consensus guidelines for advanced breast cancer (ABC 1). , 2012, Breast.

[48]  Mark Clemons,et al.  Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Chris Twelves,et al.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011, The Lancet.

[50]  J. Bergh,et al.  Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  A. Thompson,et al.  Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) , 2010, Breast Cancer Research.

[53]  J. Mackey,et al.  Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  S. Loibl,et al.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  A. Gennari.  The Impact of New Chemotherapeutic and Hormone Agents on Survival in a Population-based Cohort of Women with Metastatic Breast Cancer , 2008 .

[56]  E. Winer,et al.  Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study , 2007, Cancer.

[57]  K. Gelmon,et al.  The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer , 2007, Cancer.

[58]  G. Guyatt,et al.  Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. , 2006, Chest.

[59]  G. Hortobagyi,et al.  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  R. Weigel,et al.  Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. , 1993, Cancer research.